Guggenheim Reiterates Buy on UniQureto Buy

Benzinga01:03

Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Raises Target Price to $20

Futu News00:32 · Ratings

UniQure Is Maintained at Outperform by RBC Capital

Dow Jones00:29 · Ratings

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

Zacks Dec 11 22:30

A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $8.69 to $58

Futu NewsDec 11 21:00 · Ratings

Express News | Uniqure NV : Leerink Partners Raises Target Price to $44 From $26

BreakingsDec 11 14:20